Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001558370-23-007284
Filing Date
2023-04-28
Accepted
2023-04-28 16:15:22
Documents
15
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A apre-20221231x10ka.htm   iXBRL 10-K/A 733894
2 EX-31.3 apre-20221231xex31d3.htm EX-31.3 7294
3 EX-31.4 apre-20221231xex31d4.htm EX-31.4 8362
  Complete submission text file 0001558370-23-007284.txt   1027352

Data Files

Seq Description Document Type Size
4 EX-101.SCH apre-20221231.xsd EX-101.SCH 4247
5 EX-101.DEF apre-20221231_def.xml EX-101.DEF 21744
6 EX-101.LAB apre-20221231_lab.xml EX-101.LAB 26757
7 EX-101.PRE apre-20221231_pre.xml EX-101.PRE 16380
9 EXTRACTED XBRL INSTANCE DOCUMENT apre-20221231x10ka_htm.xml XML 8316
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 267-370-5219
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-39069 | Film No.: 23866398
SIC: 2834 Pharmaceutical Preparations